Spondyloarthritis & psoriatic arthritis
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years
Authors' conclusion
Bimekizumab was efficacious to 2 years regardless of symptom duration, with comparable 16-week treatment effect but generally better 104-week outcomes in the shorter versus longer symptom duration subgroups.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) (non-radiographic, BE MOBILE 1; radiographic, BE MOBILE 2) and the combined open-label extension
- Comparison
- Shorter vs longer symptom duration in bimekizumab efficacy
- Primary endpoint
- Efficacy outcomes of bimekizumab by symptom duration: 16-week bimekizumab vs placebo treatment effect and 104-week outcomes
- Follow-up
- Week 16 and Week 104
Methodological detailsnot powered for subgroup comparisons, not multiplicity adjusted, open-label extension to Week 104
- Not powered for subgroup comparisons
- Not multiplicity adjusted
- Open-label extension to Week 104
Primary result
As reported in the abstract
16-week bimekizumab vs placebo treatment effect, ASDAS < 2.1, BE MOBILE 1
Estimate (95% CI)
≤ 2 yearsvs > 2 yearstreatment effect comparable between subgroups
relative OR 0.82(0.22–3.08)
≤ 5 yearsvs > 5 years104-week ASDAS < 2.1 in BE MOBILE 2; significant, favouring shorter symptom duration
OR 1.94(1.02–3.68)
Original publication
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years. Arthritis Res Ther. Published 19 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →